News|Articles|November 19, 2026

Topical Docetaxel Enters Development for Extramammary Paget’s Disease

Author(s)Tim Smith
Listen
0:00 / 0:00

Key Takeaways

  • QTORIN docetaxel leverages Palvella’s topical platform to translate known docetaxel antitumor activity into a localized, potentially first-line approach for EMPD.
  • Surgical management commonly requires repeated excisions and grafting, while EMPD can invade deeper tissues, recur frequently, and occasionally disseminate systemically.
SHOW MORE

Palvella unveiled QTORIN docetaxel, a topical candidate for extramammary Paget’s disease, with FDA talks planned in early 2027 ahead of a phase 2 study.

Frequently Asked Questions:

  • What is QTORIN docetaxel?
    QTORIN docetaxel is an investigational topical form of docetaxel that Palvella Therapeutics is developing as a localized, first-line treatment for EMPD.
  • Are there any FDA-approved treatments for extramammary Paget’s disease?
    No. There are currently no FDA-approved therapies for EMPD, and management relies largely on surgery.
  • When will QTORIN docetaxel enter clinical trials?
    Palvella plans to meet with the FDA in the first half of 2027 and then start a phase 2 study.

Palvella Therapeutics has unveiled QTORIN docetaxel, an investigational topical formulation of docetaxel in development for extramammary Paget’s disease (EMPD), according to a company announcement on November 19, 2026.¹

The program is the third candidate to come out of QTORIN, Palvella’s proprietary platform for topical therapies targeting rare dermatologic conditions and vascular anomalies. No treatment is currently FDA approved for EMPD, which Palvella estimates affects more than 10,000 people in the US.¹

Why is a Topical Docetaxel Being Developed for Extramammary Paget’s Disease?

EMPD has been managed largely with surgery, and patients often undergo repeated, disfiguring procedures involving skin grafts. Recurrence is common even after treatment. According to Palvella, the disease can also extend into deeper tissue and spread systemically.¹

The scientific rationale for the program draws on clinical experience with intravenous docetaxel in metastatic EMPD. In a multicenter retrospective analysis from 12 Japanese institutions, 13 patients received monthly docetaxel as first-line chemotherapy for metastatic disease. Among the 12 patients evaluable for response, 58% achieved a partial response and the disease control rate was 83%, with a median overall survival of 16.6 months and no treatment-related deaths.²

Palvella aims to turn this systemic activity into a localized, first-line topical option that could spare patients the cumulative burden of surgery. Wes Kaupinen, Palvella’s founder and CEO, described the program as a good fit for the company’s strategy: EMPD is rare, has no approved therapies, and has a defined regulatory path.¹

What are the Next Steps for QTORIN Docetaxel?

Palvella has started investigational new drug (IND)-enabling work for QTORIN docetaxel. The company expects to meet with the FDA in the first half of 2027 and then plans to launch a phase 2 study. No clinical data for the topical formulation have been reported.¹

QTORIN docetaxel joins 2 other candidates in Palvella’s pipeline. QTORIN 3.9% rapamycin anhydrous gel is in development for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. QTORIN pitavastatin is being studied in disseminated superficial actinic porokeratosis. None of the 3 candidates has received regulatory approval for any indication.¹

References

  1. Palvella Therapeutics. Palvella Therapeutics announces QTORIN docetaxel, a new QTORIN program for the treatment of extramammary Paget’s disease (EMPD). Published November 19, 2026. Accessed November 19, 2026. https://www.globenewswire.com/news-release/2026/11/19/3406464/0/en/palvella-therapeutics-announces-qtorin-docetaxel-a-new-qtorin-program-for-the-treatment-of-extramammary-paget-s-disease-empd.html
  2. Yoshino K, Fujisawa Y, Kiyohara Y, et al. Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget’s disease. J Dermatol. 2016;43(6):633-637. doi:10.1111/1346-8138.13200

Related to this article

TanPrevent and the Case for Preventing Thousands of Melanomas
Learn why indoor tanning remains a preventable source of melanoma, what research suggests about why some patients experience difficulty stopping, and how a clinical pilot called TanPrevent could connect education with follow-up support to help them quit and stay quit.